. 2017 Mar 29;8(19):32101–32116. doi: 10.18632/oncotarget.16646

Table 2. FDA-approved antidepressants inhibit sphere formation by HCC1954 breast tumor cells.

Drug	Approved Drug Class	Molecular Target(s)	IC₅₀
Clomipramine	Tricyclic Antidepressant	SERT, 5-HT_{2A, 2C, 3, 6, 7}	1.9
Doxepin	Tricyclic Antidepressant	SERT, 5-HT_{1A, 2A, 2C, 6}	4.1
Latrepirdine	Tricyclic Antihistamine	5-HT_{2C, 5A, 6}	4.2
Cyproheptadine	Tricyclic Antihistamine	5-HT_{1A, 2A, 2B, 2C, 3, 6, 7}	6.0
Mianserin	Tetracyclic Antidepressant	5-HT_{1F, 2A, 2B, 2C, 6, 7}	12.5
Ziprasidone	Atypical Antipsychotic	SERT, 5-HT_{1A, 1B, 1D, 2A, 2C, 6, 7}	0.8
Asenapine	Atypical Antipsychotic	5-HT_{1A, 1B, 2A, 2B, 2C, 5A, 6, 7}	7.5
Vortioxetine	Selective Serotonin Reuptake Inhibitor	SERT, 5-HT_{1A, 1B, 1D, 3A, 7}	1.1
Vilazodone	Selective Serotonin Reuptake Inhibitor	SERT, 5-HT_1A	1.6
Fluoxetine	Selective Serotonin Reuptake Inhibitor	SERT, 5-HT_{2A, 2C}	3.4
Paroxetine	Selective Serotonin Reuptake Inhibitor	SERT	2.7
Sertraline	Selective Serotonin Reuptake Inhibitor	SERT	1.1

HCC1954 tumorspheres were grown in the presence of different FDA-approved serotonergic antidepressants and their effect on sphere formation monitored. All the antidepressants reduced sphere formation in a dose-dependent fashion. IC₅₀ values (listed in μM) were calculated using Graphpad Prism 6. The IC₅₀ values of the drugs were determined in two biological experiments.